BofA Securities Upgrades Y-mAbs Therapeutics (YMAB) to Buy
Tweet
Share
E-mail
Get Alerts YMAB Hot Sheet
Price: $8.61 --0%
Rating Summary:
5 Buy, 11 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 19 | Down: 16 | New: 9
Rating Summary:
5 Buy, 11 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 19 | Down: 16 | New: 9
Join SI Premium – FREE
BofA Securities analyst Alec Stranahan upgraded Y-mAbs Therapeutics (NASDAQ: YMAB) from Neutral to Buy with a price target of $56.00.
For an analyst ratings summary and ratings history on Y-mAbs Therapeutics click here. For more ratings news on Y-mAbs Therapeutics click here.
Shares of Y-mAbs Therapeutics closed at $28.65 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Northland Upgrades Hyliion Holdings (HYLN) to Outperform 'on Improved Visibility to KARNO Commercialization'
- Wolfe Research Upgrades Abbott Labs (ABT) to Outperform
- Applied Aerospace & Defense (AADX) PT Lowered to $23 at BofA Securities
Create E-mail Alert Related Categories
UpgradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
